ClinicalTrials.gg
CompletedNCT04530344Updated Aug 14, 2025Results posted

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

A Phase 3 interventional study of ruxolitinib and Vehicle in Vitiligo, sponsored by Incyte Corporation. Completed at 84 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
Largest of 14
458 · median 90
Started
2020
the only one that year
Phase 3
6 of 14
3 open now
Registered
5th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one has the largest enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 5th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • INCB018424
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.
  • Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.
  • Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
  • Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.
  • Male and female participants must be willing to take appropriate measures to avoid pregnancy or fathering a child.
  • Ability to comprehend and willingness to sign an ICF or written of the parent(s) or legal guardian and written assent from the participant when possible.

Exclusion criteria

Exclusion Criteria:

  • Has been permanently discontinued from study treatment in the parent study for any reason.
  • Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
  • Pregnant or breastfeeding woman.
  • Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    Cohort A : ruxolitinib cream

    Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.

    Drug: ruxolitinib

  • Placebo comparator
    Cohort A : Vehicle

    Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.

    Drug: Vehicle

  • Experimental
    Cohort B : roxolitinib cream

    Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.

    Drug: ruxolitinib

Interventions

  • ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.

    Also known as: INCB018424 Cream

  • DrugVehicle

    Vehicle cream is a topical formulation applied as a thin film to affected areas.

06

What researchers measure

Primary outcomes

  1. Time to Relapse (Defined as <F-VASI75)

    Relapse was defined as a loss of 75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<75%.

    Time frame: from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)

Secondary outcomes

  1. Time to Loss of Adequate Response

    Loss of adequate response was defined as a loss of 90% improvement from Baseline in the F-VASI score (F-VASI90) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<90%.

    Time frame: from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)

  2. Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  3. Percentage of Participants Achieving a ≥75% Improvement From Baseline in the F-VASI (F-VASI75) Score During the Extension Treatment Period

    An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  4. Percentage of Participants Achieving a ≥90% Improvement From Baseline in the F-VASI (F-VASI90) Score During the Extension Treatment Period

    An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  5. Mean F-VASI Scores During the Extension Treatment Period

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  6. Change From Baseline in F-VASI Scores During the Extension Treatment Period

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  7. Percent Change From Baseline in F-VASI Scores During the Extension Treatment Period

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline (BL); up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  8. Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score During the Extension Treatment Period

    A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  9. Percentage of Participants Achieving a ≥75% Improvement From Baseline in the T-VASI (T-VASI75) Score During the Extension Treatment Period

    A T-VASI75 responder achieved at least 75% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  10. Percentage of Participants Achieving a ≥90% Improvement From Baseline in the T-VASI (T-VASI90) Score During the Extension Treatment Period

    A T-VASI90 responder achieved at least 90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  11. Mean T-VASI Scores During the Extension Treatment Period

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  12. Change From Baseline in T-VASI Scores During the Extension Treatment Period

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline=post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  13. Percent Change From Baseline in T-VASI Scores During the Extension Treatment Period

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  14. Mean Facial Body Surface Area (F-BSA) During the Extension Treatment Period

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  15. Change From Baseline in F-BSA During the Extension Treatment Period

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  16. Percent Change From Baseline in F-BSA During the Extension Treatment Period

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  17. Mean Total Body Surface Area (T-BSA) During the Extension Treatment Period

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the total body.

    Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  18. Change From Baseline in T-BSA During the Extension Treatment Period

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the total body.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  19. Percent Change From Baseline in T-BSA During the Extension Treatment Period

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  20. Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5 During the Extension Treatment Period

    The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

    Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  21. Change From Week 52 in Dermatology Life Quality Index (DLQI) Total Score During the Extension Treatment Period

    The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age ≥16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relations (Questions 8 and 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "prevented work or studying"=3. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.

    Time frame: Week 52; up to up to Week 104 of Extension Study (Week 52 was the first visit of this Treatment Extension study.)

  22. Change From Week 52 in Children's Dermatology Life Quality Index (CDLQI) Total Score During the Extension Treatment Period

    The CDLQI is the youth/children's version of the DLQI. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age \<16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5, and 6); School or holidays (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.

    Time frame: Week 52; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)

  23. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as any adverse event (AE) reported for the first time or the worsening of a pre-existing event after the first application of study drug in this study. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.

    Time frame: up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.)

  24. Trough Plasma Concentrations of Ruxolitinib at Week 80 and Week 104

    The steady-state plasma concentration was assessed. Pharmacokinetic blood samples could have been collected at any time prior to study drug application at the site at the Week 80 visit and at any time at the Week 104 (End of Trial) visit. Results from the two parent studies indicated that steady state was reached at or before Week 4, and that, hence, the use of vehicle or ruxolitinib 1.5% in the first 52 weeks of treatment had no impact on the ruxolitinib plasma concentration at the Week 80 and Week 104 (End of Treatment) visits. Thus, the two Cohort B cohorts were combined into a single arm for data analysis in this study.

    Time frame: Weeks 80 (predose); Week 104 (any time post-dose) (Week 52 was the first visit of this Treatment Extension study.)

07

Results

Posted Jul 19, 2023
Limitations and caveats
Data from participants at a single site (N = 2) were removed from all efficacy analyses performed on the ITT-Ext Population and FAS Cohort A owing to noncompliance with the Protocol in the parent study resulting in serious concerns with data quality.

Participant flow

This study was conducted at 87 study centers in North America and Europe.

Participant flow — Overall Study
MilestoneCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Started5858118224
Completed415092173
Not completed1782651
Withdrew: Lost to follow-up33310
Withdrew: Withdrawal by subject1451833
Withdrew: Adverse event0001
Withdrew: Lack of efficacy0001
Withdrew: Physician decision0011
Withdrew: Pregnancy0021
Withdrew: Protocol violation0001
Withdrew: Site closed due to noncompliance0001
Withdrew: Discontinued due to covid-19 pandemic0010
Withdrew: Missed safety follow-up visit0010
Withdrew: Personal reasons0001
Withdrew: Not compliant with protocol-specific visit window0001

Outcome measures

PrimaryTime to Relapse (Defined as <F-VASI75)

Relapse was defined as a loss of 75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<75%.

Time frame:
from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)
Reported as:
Median · days
Time to Relapse (Defined as <F-VASI75)
daysCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Time to Relapse (Defined as <F-VASI75)NA (238.0 to NA)NA (NA to NA)——
Statistical analysis
  • Cohort A: Vehicle Cream BID vs Cohort A: Ruxolitinib 1.5% Cream BID · Log Rank · p = 0.0414 · Hazard ratio (hr): 0.422 · 95% CI 0.180 to 0.990The p-value was based on the log-rank test stratified by randomization stratification factor between treatment and vehicle.
SecondaryTime to Loss of Adequate Response

Loss of adequate response was defined as a loss of 90% improvement from Baseline in the F-VASI score (F-VASI90) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<90%.

Time frame:
from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)
Reported as:
Median · days
Time to Loss of Adequate Response
daysCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Time to Loss of Adequate Response195.0 (113.0 to 372.0)NA (NA to NA)——
Statistical analysis
  • Cohort A: Vehicle Cream BID vs Cohort A: Ruxolitinib 1.5% Cream BID · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.316 · 95% CI 0.165 to 0.606The p-value was based on the log-rank test stratified by randomization stratification factor between treatment and vehicle.
SecondaryPercentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5298.2 (90.6 to 100.0)98.2 (90.6 to 100.0)45.8 (36.6 to 55.2)65.6 (58.9 to 71.9)
Week 5698.2 (90.4 to 100.0)96.4 (87.5 to 99.6)50.0 (40.2 to 59.8)69.4 (62.8 to 75.5)
Week 6097.9 (88.9 to 99.9)98.1 (89.7 to 100.0)54.2 (44.3 to 63.9)69.2 (62.5 to 75.4)
Week 6497.7 (87.7 to 99.9)100.0 (92.1 to 100.0)58.3 (48.5 to 67.7)72.0 (65.3 to 78.0)
Week 6895.1 (83.5 to 99.4)100.0 (92.1 to 100.0)63.6 (53.7 to 72.6)77.1 (70.9 to 82.6)
Week 8096.7 (82.8 to 99.9)100.0 (92.1 to 100.0)65.7 (55.4 to 74.9)78.9 (72.4 to 84.4)
Week 92100.0 (85.2 to 100.0)97.7 (87.7 to 99.9)66.0 (55.5 to 75.4)84.4 (78.2 to 89.3)
Week 10495.7 (78.1 to 99.9)100.0 (90.7 to 100.0)69.9 (59.5 to 79.0)86.4 (80.5 to 91.1)
SecondaryPercentage of Participants Achieving a ≥75% Improvement From Baseline in the F-VASI (F-VASI75) Score During the Extension Treatment Period

An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the F-VASI (F-VASI75) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5298.2 (90.6 to 100.0)98.2 (90.6 to 100.0)16.1 (10.0 to 24.0)30.8 (24.8 to 37.3)
Week 5696.4 (87.7 to 99.6)96.4 (87.5 to 99.6)23.1 (15.6 to 32.2)34.7 (28.4 to 41.5)
Week 6095.8 (85.7 to 99.5)90.4 (79.0 to 96.8)29.0 (20.6 to 38.5)40.8 (34.1 to 47.7)
Week 6495.3 (84.2 to 99.4)97.8 (88.2 to 99.9)30.6 (22.1 to 40.2)43.5 (36.6 to 50.5)
Week 6887.8 (73.8 to 95.9)100.0 (92.1 to 100.0)34.6 (25.6 to 44.4)48.6 (41.6 to 55.5)
Week 8090.0 (73.5 to 97.9)100.0 (92.1 to 100.0)43.4 (33.5 to 53.8)54.6 (47.4 to 61.8)
Week 92100.0 (85.2 to 100.0)97.7 (87.7 to 99.9)47.9 (37.5 to 58.4)60.3 (52.8 to 67.6)
Week 10495.7 (78.1 to 99.9)97.4 (86.2 to 99.9)47.3 (36.9 to 57.9)66.1 (58.6 to 73.0)
SecondaryPercentage of Participants Achieving a ≥90% Improvement From Baseline in the F-VASI (F-VASI90) Score During the Extension Treatment Period

An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the F-VASI (F-VASI90) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5298.2 (90.6 to 100.0)96.5 (87.9 to 99.6)0.0 (0.0 to 3.1)2.3 (0.7 to 5.2)
Week 5689.3 (78.1 to 96.0)94.5 (84.9 to 98.9)3.7 (1.0 to 9.2)8.3 (5.0 to 12.9)
Week 6083.3 (69.8 to 92.5)86.5 (74.2 to 94.4)8.4 (3.9 to 15.4)15.2 (10.6 to 20.7)
Week 6472.1 (56.3 to 84.7)93.3 (81.7 to 98.6)11.1 (5.9 to 18.6)15.5 (10.8 to 21.1)
Week 6868.3 (51.9 to 81.9)95.6 (84.9 to 99.5)12.1 (6.6 to 19.9)22.4 (16.9 to 28.6)
Week 8080.0 (61.4 to 92.3)97.8 (88.2 to 99.9)22.2 (14.5 to 31.7)30.4 (24.0 to 37.4)
Week 9278.3 (56.3 to 92.5)93.0 (80.9 to 98.5)24.5 (16.2 to 34.4)32.4 (25.6 to 39.8)
Week 10469.6 (47.1 to 86.8)92.1 (78.6 to 98.3)28.0 (19.1 to 38.2)33.9 (27.0 to 41.4)
SecondaryMean F-VASI Scores During the Extension Treatment Period

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Mean F-VASI Scores During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Baseline0.86 ± 0.4920.99 ± 0.6440.88 ± 0.5430.91 ± 0.550
Week 520.05 ± 0.1100.07 ± 0.1810.51 ± 0.4590.39 ± 0.374
Week 560.05 ± 0.1080.07 ± 0.1860.50 ± 0.4750.38 ± 0.372
Week 600.06 ± 0.1450.09 ± 0.1860.45 ± 0.4500.35 ± 0.375
Week 640.08 ± 0.1310.08 ± 0.2300.43 ± 0.4560.33 ± 0.350
Week 680.11 ± 0.1990.04 ± 0.0810.40 ± 0.4300.31 ± 0.352
Week 800.05 ± 0.0820.04 ± 0.1080.36 ± 0.4260.27 ± 0.345
Week 920.04 ± 0.0550.04 ± 0.0760.38 ± 0.4710.23 ± 0.281
Week 1040.06 ± 0.1090.04 ± 0.0830.37 ± 0.4930.21 ± 0.280
SecondaryChange From Baseline in F-VASI Scores During the Extension Treatment Period

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Change From Baseline in F-VASI Scores During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-0.81 ± 0.464-0.92 ± 0.591-0.37 ± 0.346-0.51 ± 0.448
Week 56-0.82 ± 0.492-0.90 ± 0.594-0.39 ± 0.370-0.54 ± 0.457
Week 60-0.84 ± 0.447-0.87 ± 0.570-0.43 ± 0.402-0.55 ± 0.457
Week 64-0.80 ± 0.442-0.87 ± 0.527-0.44 ± 0.423-0.58 ± 0.452
Week 68-0.73 ± 0.316-0.86 ± 0.518-0.46 ± 0.437-0.61 ± 0.476
Week 80-0.75 ± 0.360-0.86 ± 0.508-0.49 ± 0.471-0.64 ± 0.478
Week 92-0.76 ± 0.341-0.87 ± 0.548-0.48 ± 0.531-0.69 ± 0.488
Week 104-0.72 ± 0.380-0.92 ± 0.561-0.50 ± 0.557-0.68 ± 0.514
SecondaryPercent Change From Baseline in F-VASI Scores During the Extension Treatment Period

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline (BL); up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage change
Percent Change From Baseline in F-VASI Scores During the Extension Treatment Period
percentage changeCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-94.45 ± 14.069-94.50 ± 8.990-44.32 ± 27.775-54.72 ± 31.006
Week 56-93.79 ± 14.981-93.21 ± 12.573-46.19 ± 30.728-57.38 ± 31.256
Week 60-93.85 ± 9.087-92.04 ± 13.198-50.55 ± 30.537-60.17 ± 30.147
Week 64-89.64 ± 23.562-94.87 ± 8.079-52.32 ± 32.826-62.94 ± 27.427
Week 68-87.98 ± 19.644-96.25 ± 4.633-55.27 ± 32.433-65.55 ± 30.388
Week 80-93.24 ± 13.062-96.65 ± 4.683-58.60 ± 34.839-69.38 ± 29.091
Week 92-95.77 ± 5.586-94.95 ± 10.366-55.44 ± 49.855-73.77 ± 25.490
Week 104-90.53 ± 17.763-95.86 ± 7.213-56.53 ± 57.087-73.84 ± 31.780
SecondaryPercentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score During the Extension Treatment Period

A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5280.7 (68.1 to 90.0)71.9 (58.5 to 83.0)16.9 (10.7 to 25.0)42.5 (35.9 to 49.3)
Week 5676.8 (63.6 to 87.0)72.7 (59.0 to 83.9)16.7 (10.2 to 25.1)45.8 (39.1 to 52.7)
Week 6083.3 (69.8 to 92.5)75.0 (61.1 to 86.0)19.6 (12.6 to 28.4)49.8 (42.8 to 56.7)
Week 6474.4 (58.8 to 86.5)82.2 (67.9 to 92.0)21.3 (14.0 to 30.2)50.7 (43.7 to 57.7)
Week 6870.7 (54.5 to 83.9)84.4 (70.5 to 93.5)29.9 (21.4 to 39.5)54.3 (47.3 to 61.2)
Week 8080.0 (61.4 to 92.3)86.7 (73.2 to 94.9)39.4 (29.7 to 49.7)57.7 (50.4 to 64.8)
Week 9273.9 (51.6 to 89.8)86.0 (72.1 to 94.7)48.9 (38.5 to 59.5)61.5 (53.9 to 68.6)
Week 10460.9 (38.5 to 80.3)89.5 (75.2 to 97.1)54.8 (44.2 to 65.2)63.8 (56.3 to 70.9)
SecondaryPercentage of Participants Achieving a ≥75% Improvement From Baseline in the T-VASI (T-VASI75) Score During the Extension Treatment Period

A T-VASI75 responder achieved at least 75% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the T-VASI (T-VASI75) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5238.6 (26.0 to 52.4)42.1 (29.1 to 55.9)3.4 (0.9 to 8.5)12.2 (8.2 to 17.3)
Week 5642.9 (29.7 to 56.8)43.6 (30.3 to 57.7)4.6 (1.5 to 10.5)13.4 (9.2 to 18.7)
Week 6045.8 (31.4 to 60.8)38.5 (25.3 to 53.0)4.7 (1.5 to 10.6)14.2 (9.8 to 19.7)
Week 6439.5 (25.0 to 55.6)48.9 (33.7 to 64.2)3.7 (1.0 to 9.2)16.9 (12.1 to 22.7)
Week 6839.0 (24.2 to 55.5)42.2 (27.7 to 57.8)6.5 (2.7 to 13.0)22.4 (16.9 to 28.6)
Week 8053.3 (34.3 to 71.7)48.9 (33.7 to 64.2)10.1 (5.0 to 17.8)23.7 (17.9 to 30.3)
Week 9243.5 (23.2 to 65.5)53.5 (37.7 to 68.8)12.8 (6.8 to 21.2)29.1 (22.5 to 36.3)
Week 10439.1 (19.7 to 61.5)55.3 (38.3 to 71.4)18.3 (11.0 to 27.6)30.5 (23.8 to 37.9)
SecondaryPercentage of Participants Achieving a ≥90% Improvement From Baseline in the T-VASI (T-VASI90) Score During the Extension Treatment Period

A T-VASI90 responder achieved at least 90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the T-VASI (T-VASI90) Score During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5212.3 (5.1 to 23.7)12.3 (5.1 to 23.7)0.0 (0.0 to 3.1)2.3 (0.7 to 5.2)
Week 5612.5 (5.2 to 24.1)14.5 (6.5 to 26.7)0.0 (0.0 to 3.4)3.2 (1.3 to 6.6)
Week 6016.7 (7.5 to 30.2)17.3 (8.2 to 30.3)0.0 (0.0 to 3.4)3.8 (1.7 to 7.3)
Week 6420.9 (10.0 to 36.0)20.0 (9.6 to 34.6)0.0 (0.0 to 3.4)2.9 (1.1 to 6.2)
Week 6822.0 (10.6 to 37.6)20.0 (9.6 to 34.6)0.9 (0.0 to 5.1)4.3 (2.0 to 8.0)
Week 8020.0 (7.7 to 38.6)20.0 (9.6 to 34.6)1.0 (0.0 to 5.5)6.7 (3.6 to 11.2)
Week 9221.7 (7.5 to 43.7)20.9 (10.0 to 36.0)2.1 (0.3 to 7.5)8.9 (5.2 to 14.1)
Week 10421.7 (7.5 to 43.7)23.7 (11.4 to 40.2)3.2 (0.7 to 9.1)9.6 (5.7 to 14.9)
SecondaryMean T-VASI Scores During the Extension Treatment Period

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Mean T-VASI Scores During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Baseline6.06 ± 2.0566.27 ± 2.0306.69 ± 2.1506.74 ± 2.006
Week 522.38 ± 2.2062.36 ± 1.8055.25 ± 3.2483.90 ± 2.132
Week 562.39 ± 2.2532.31 ± 1.8435.06 ± 3.1513.80 ± 2.213
Week 602.21 ± 2.1762.30 ± 1.8414.86 ± 3.1503.58 ± 2.122
Week 642.33 ± 2.2101.94 ± 1.7174.85 ± 3.3173.57 ± 2.051
Week 682.45 ± 2.2311.76 ± 1.3784.51 ± 3.0603.43 ± 2.160
Week 802.05 ± 2.2331.73 ± 1.3314.18 ± 3.0363.18 ± 2.017
Week 922.17 ± 1.9131.65 ± 1.2444.12 ± 3.4773.04 ± 2.128
Week 1042.86 ± 3.2691.54 ± 1.2274.00 ± 4.2082.92 ± 2.061
SecondaryChange From Baseline in T-VASI Scores During the Extension Treatment Period

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline=post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Change From Baseline in T-VASI Scores During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-3.68 ± 1.564-3.91 ± 1.526-1.45 ± 2.271-2.83 ± 1.938
Week 56-3.71 ± 1.615-3.91 ± 1.503-1.69 ± 2.217-2.97 ± 2.086
Week 60-3.79 ± 1.692-3.95 ± 1.585-1.83 ± 2.161-3.16 ± 2.027
Week 64-3.60 ± 2.033-4.20 ± 1.569-1.84 ± 2.375-3.21 ± 2.060
Week 68-3.44 ± 1.789-4.24 ± 1.534-2.21 ± 2.273-3.35 ± 2.143
Week 80-3.79 ± 1.663-4.26 ± 1.519-2.49 ± 2.175-3.55 ± 2.109
Week 92-3.85 ± 1.545-4.33 ± 1.673-2.61 ± 2.624-3.73 ± 2.246
Week 104-3.05 ± 2.156-4.48 ± 1.702-2.71 ± 3.479-3.84 ± 2.151
SecondaryPercent Change From Baseline in T-VASI Scores During the Extension Treatment Period

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage change
Percent Change From Baseline in T-VASI Scores During the Extension Treatment Period
percentage changeCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-65.01 ± 23.969-64.95 ± 21.547-24.75 ± 2.271-42.14 ± 25.783
Week 56-65.16 ± 24.916-65.69 ± 22.042-28.05 ± 30.487-43.91 ± 27.408
Week 60-66.83 ± 26.478-65.58 ± 22.910-31.01 ± 28.944-47.00 ± 26.089
Week 64-62.82 ± 33.328-70.44 ± 20.212-30.85 ± 32.898-46.96 ± 26.395
Week 68-61.40 ± 29.204-71.89 ± 17.942-35.53 ± 32.135-49.41 ± 27.629
Week 80-68.99 ± 26.870-72.21 ± 17.852-40.97 ± 30.033-52.48 ± 26.991
Week 92-66.95 ± 24.885-72.55 ± 19.152-43.34 ± 34.425-55.00 ± 28.995
Week 104-58.38 ± 35.533-74.66 ± 17.727-45.52 ± 41.968-56.96 ± 27.409
SecondaryMean Facial Body Surface Area (F-BSA) During the Extension Treatment Period

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage BSA
Mean Facial Body Surface Area (F-BSA) During the Extension Treatment Period
percentage BSACohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Baseline0.92 ± 0.4981.10 ± 0.7451.01 ± 0.6321.02 ± 0.636
Week 520.18 ± 0.2400.27 ± 0.4010.81 ± 0.6410.70 ± 0.568
Week 560.18 ± 0.1980.27 ± 0.4160.77 ± 0.6380.67 ± 0.572
Week 600.20 ± 0.2250.25 ± 0.3090.73 ± 0.6160.63 ± 0.557
Week 640.20 ± 0.2060.20 ± 0.2710.71 ± 0.6070.61 ± 0.566
Week 680.22 ± 0.2580.16 ± 0.1830.67 ± 0.5810.57 ± 0.548
Week 800.12 ± 0.1380.15 ± 0.2000.62 ± 0.5650.55 ± 0.564
Week 920.10 ± 0.1300.15 ± 0.1800.64 ± 0.5950.49 ± 0.527
Week 1040.13 ± 0.1540.15 ± 0.1810.62 ± 0.6020.47 ± 0.509
SecondaryChange From Baseline in F-BSA During the Extension Treatment Period

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage BSA
Change From Baseline in F-BSA During the Extension Treatment Period
percentage BSACohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-0.74 ± 0.402-0.83 ± 0.638-0.20 ± 0.313-0.31 ± 0.435
Week 56-0.76 ± 0.458-0.82 ± 0.672-0.25 ± 0.345-0.35 ± 0.433
Week 60-0.77 ± 0.441-0.80 ± 0.601-0.28 ± 0.364-0.38 ± 0.454
Week 64-0.74 ± 0.446-0.83 ± 0.625-0.29 ± 0.417-0.41 ± 0.457
Week 68-0.69 ± 0.345-0.86 ± 0.657-0.31 ± 0.425-0.45 ± 0.489
Week 80-0.74 ± 0.381-0.87 ± 0.637-0.37 ± 0.494-0.48 ± 0.521
Week 92-0.76 ± 0.374-0.87 ± 0.678-0.36 ± 0.558-0.54 ± 0.532
Week 104-0.70 ± 0.400-0.93 ± 0.716-0.39 ± 0.604-0.54 ± 0.548
SecondaryPercent Change From Baseline in F-BSA During the Extension Treatment Period

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage change
Percent Change From Baseline in F-BSA During the Extension Treatment Period
percentage changeCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-80.75 ± 18.726-76.75 ± 23.470-22.15 ± 28.268-29.06 ± 36.354
Week 56-80.23 ± 21.828-74.42 ± 35.048-26.20 ± 30.604-33.66 ± 33.944
Week 60-79.20 ± 19.463-77.67 ± 20.946-30.04 ± 30.751-36.86 ± 33.289
Week 64-75.92 ± 32.175-80.06 ± 22.142-30.67 ± 33.473-39.58 ± 31.992
Week 68-77.11 ± 23.565-83.14 ± 21.999-32.60 ± 34.575-43.61 ± 32.549
Week 80-84.55 ± 18.730-84.67 ± 22.014-36.79 ± 36.826-46.38 ± 34.407
Week 92-87.81 ± 15.738-83.24 ± 23.746-34.05 ± 50.762-51.96 ± 31.510
Week 104-82.87 ± 23.245-84.09 ± 22.920-35.82 ± 52.646-52.85 ± 32.983
SecondaryMean Total Body Surface Area (T-BSA) During the Extension Treatment Period

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the total body.

Time frame:
up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage BSA
Mean Total Body Surface Area (T-BSA) During the Extension Treatment Period
percentage BSACohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Baseline6.79 ± 2.1576.85 ± 1.9247.42 ± 2.0647.49 ± 2.006
Week 524.09 ± 2.8384.20 ± 2.6406.95 ± 3.4035.96 ± 2.352
Week 564.11 ± 2.8804.13 ± 2.7886.73 ± 3.2815.81 ± 2.558
Week 603.77 ± 2.7564.09 ± 2.8336.61 ± 3.2625.64 ± 2.479
Week 643.98 ± 3.0873.49 ± 2.4526.67 ± 3.4485.64 ± 2.483
Week 683.92 ± 2.8133.27 ± 2.3106.46 ± 3.2395.51 ± 2.682
Week 803.72 ± 3.1513.18 ± 2.2326.09 ± 3.3135.27 ± 2.581
Week 923.94 ± 2.8343.04 ± 2.1945.96 ± 3.6465.15 ± 2.741
Week 1044.56 ± 4.1562.93 ± 2.3015.91 ± 4.4755.07 ± 2.699
SecondaryChange From Baseline in T-BSA During the Extension Treatment Period

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the total body.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage BSA
Change From Baseline in T-BSA During the Extension Treatment Period
percentage BSACohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-2.70 ± 1.830-2.64 ± 1.906-0.47 ± 2.325-1.52 ± 1.711
Week 56-2.74 ± 1.918-2.70 ± 1.983-0.73 ± 2.238-1.71 ± 2.059
Week 60-2.95 ± 1.910-2.75 ± 2.195-0.80 ± 2.128-1.86 ± 1.978
Week 64-2.73 ± 2.528-3.22 ± 1.883-0.73 ± 2.432-1.90 ± 2.052
Week 68-2.73 ± 1.958-3.34 ± 1.922-0.98 ± 2.262-2.03 ± 2.180
Week 80-3.05 ± 2.083-3.42 ± 1.809-1.31 ± 2.341-2.21 ± 2.169
Week 92-3.03 ± 1.664-3.58 ± 1.938-1.49 ± 2.753-2.36 ± 2.380
Week 104-2.18 ± 2.723-3.72 ± 2.075-1.52 ± 3.672-2.42 ± 2.307
SecondaryPercent Change From Baseline in T-BSA During the Extension Treatment Period

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · percentage change
Percent Change From Baseline in T-BSA During the Extension Treatment Period
percentage changeCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 52-43.81 ± 27.916-41.50 ± 28.747-8.54 ± 28.806-20.57 ± 23.042
Week 56-44.22 ± 29.590-43.12 ± 29.489-11.96 ± 28.156-22.98 ± 26.032
Week 60-47.61 ± 29.237-43.09 ± 31.608-13.40 ± 26.410-25.12 ± 25.564
Week 64-43.29 ± 40.045-50.59 ± 27.166-12.00 ± 30.202-25.15 ± 26.860
Week 68-44.53 ± 30.086-52.51 ± 26.921-15.01 ± 29.093-27.59 ± 28.476
Week 80-50.51 ± 33.794-53.98 ± 25.682-20.22 ± 30.154-29.92 ± 27.996
Week 92-48.53 ± 29.457-55.56 ± 26.401-22.84 ± 33.708-31.98 ± 30.805
Week 104-40.84 ± 40.076-57.40 ± 27.898-24.26 ± 42.193-32.96 ± 29.907
SecondaryPercentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5 During the Extension Treatment Period

The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

Time frame:
Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5 During the Extension Treatment Period
percentage of participantsCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 5249.1 (35.6 to 62.7)42.1 (29.1 to 55.9)11.9 (6.6 to 19.1)35.3 (29.0 to 42.0)
Week 5648.2 (34.7 to 62.0)34.5 (22.2 to 48.6)20.4 (13.2 to 29.2)30.1 (24.1 to 36.7)
Week 6046.9 (32.5 to 61.7)28.8 (17.1 to 43.1)19.6 (12.6 to 28.4)27.6 (21.7 to 34.2)
Week 6453.5 (37.7 to 68.8)37.8 (23.8 to 53.5)23.1 (15.6 to 32.2)28.2 (22.1 to 34.8)
Week 6846.3 (30.7 to 62.6)46.7 (31.7 to 62.1)20.6 (13.4 to 29.5)33.8 (27.4 to 40.6)
Week 8038.7 (21.8 to 57.8)42.2 (27.7 to 57.8)28.3 (19.7 to 38.2)32.8 (26.3 to 39.9)
Week 9239.1 (19.7 to 61.5)37.2 (23.0 to 53.3)28.4 (19.6 to 38.6)41.1 (33.8 to 48.7)
Week 10456.5 (34.5 to 76.8)50.0 (33.4 to 66.6)30.1 (21.0 to 40.5)43.3 (35.9 to 50.9)
SecondaryChange From Week 52 in Dermatology Life Quality Index (DLQI) Total Score During the Extension Treatment Period

The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age ≥16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relations (Questions 8 and 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "prevented work or studying"=3. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.

Time frame:
Week 52; up to up to Week 104 of Extension Study (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Change From Week 52 in Dermatology Life Quality Index (DLQI) Total Score During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 522.87 ± 3.0594.10 ± 4.7843.69 ± 3.4283.53 ± 4.150
Change from Week 52 at Week 560.11 ± 2.054-0.47 ± 1.757-0.05 ± 2.138-0.22 ± 2.483
Change from Week 52 at Week 600.37 ± 2.3880.13 ± 2.2270.28 ± 2.4910.24 ± 2.929
Change from Week 52 at Week 640.35 ± 2.5780.18 ± 2.630-0.06 ± 2.712-0.14 ± 2.350
Change from Week 52 at Week 68-0.08 ± 2.508-0.15 ± 2.202-0.17 ± 2.5010.08 ± 2.454
Change from Week 52 at Week 800.03 ± 3.006-0.23 ± 2.315-0.77 ± 2.871-0.13 ± 2.809
Change from Week 52 at Week 920.27 ± 2.354-0.23 ± 1.898-0.89 ± 2.383-0.22 ± 2.941
Change from Week 52 at Week 1040.57 ± 2.135-0.40 ± 1.538-0.48 ± 2.277-0.06 ± 2.813
SecondaryChange From Week 52 in Children's Dermatology Life Quality Index (CDLQI) Total Score During the Extension Treatment Period

The CDLQI is the youth/children's version of the DLQI. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age \<16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5, and 6); School or holidays (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.

Time frame:
Week 52; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · scores on a scale
Change From Week 52 in Children's Dermatology Life Quality Index (CDLQI) Total Score During the Extension Treatment Period
scores on a scaleCohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Week 521.67 ± 2.8871.00 ± 0.6321.25 ± 1.8932.32 ± 3.872
Change from Week 52 at Week 56-1.00 ± 2.646-0.17 ± 0.7530.00 ± 0.8160.36 ± 1.989
Change from Week 52 at Week 600.00 ± 0.000-0.50 ± 0.548-0.50 ± 0.577-0.41 ± 2.108
Change from Week 52 at Week 64-1.33 ± 2.3090.00 ± 0.707-1.00 ± 1.414-0.36 ± 1.399
Change from Week 52 at Week 68-0.67 ± 1.1550.40 ± 1.1400.50 ± 0.577-0.23 ± 1.541
Change from Week 52 at Week 80-2.00 ± 2.828-0.40 ± 0.548-0.75 ± 1.7080.15 ± 1.814
Change from Week 52 at Week 92NA ± NA0.25 ± 1.258-0.25 ± 0.9570.70 ± 3.614
Change from Week 52 at Week 104-0.50 ± 0.707-0.67 ± 1.155-1.25 ± 1.893-0.20 ± 4.086
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as any adverse event (AE) reported for the first time or the worsening of a pre-existing event after the first application of study drug in this study. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.

Time frame:
up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsCohort A: Vehicle Cream BIDCohort A: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)2133259114
SecondaryTrough Plasma Concentrations of Ruxolitinib at Week 80 and Week 104

The steady-state plasma concentration was assessed. Pharmacokinetic blood samples could have been collected at any time prior to study drug application at the site at the Week 80 visit and at any time at the Week 104 (End of Trial) visit. Results from the two parent studies indicated that steady state was reached at or before Week 4, and that, hence, the use of vehicle or ruxolitinib 1.5% in the first 52 weeks of treatment had no impact on the ruxolitinib plasma concentration at the Week 80 and Week 104 (End of Treatment) visits. Thus, the two Cohort B cohorts were combined into a single arm for data analysis in this study.

Time frame:
Weeks 80 (predose); Week 104 (any time post-dose) (Week 52 was the first visit of this Treatment Extension study.)
Reported as:
Mean · nanomolar
Trough Plasma Concentrations of Ruxolitinib at Week 80 and Week 104
nanomolarCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BIDCohorts A and B: Ruxolitinib 1.5% Cream BID
12 to <18 years7.28 ± 11.75.56 ± 10.55.85 ± 10.6
18 to <65 years15.1 ± 19.512.7 ± 17.213.1 ± 17.6
≥65 years13.0 ± 9.4425.7 ± 20.924.3 ± 20.2
Overall13.8 ± 18.112.8 ± 17.412.9 ± 17.5

Adverse events

Collected over up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/58 (0%)0/58 (0%)6/58 (10.3%)
Ruxolitinib 1.5% Cream BID0/423 (0%)12/423 (2.8%)55/423 (13%)
Total0/458 (0%)12/458 (2.6%)61/458 (13.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BIDTotal
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/581/4231/458
Angina pectorisCardiac disorders0/581/4231/458
Bipolar I disorderPsychiatric disorders0/581/4231/458
COVID-19 pneumoniaInfections and infestations0/581/4231/458
CholelithiasisHepatobiliary disorders0/581/4231/458
CystoceleReproductive system and breast disorders0/581/4231/458
Hip fractureInjury, poisoning and procedural complications0/581/4231/458
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/581/4231/458
Mental status changesPsychiatric disorders0/581/4231/458
OtosclerosisEar and labyrinth disorders0/581/4231/458
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BIDTotal
COVID-19Infections and infestations6/5855/42361/458

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Mean39.3 ± 12.4942.9 ± 15.9539.7 ± 14.6239.3 ± 16.4539.9 ± 15.47
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Female313361129254
Male27255795204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Asian433818
Black or African American5431123
Native Hawaiian or Other Pacific Islander10012
Not Reported2131319
White4248107180377
Captured as Latino in Database10001
Persian10001
Indo-Caribbean10001
Jordanian10001
Brazilian01001
Guyana01001
American Indian or Alaska Native00011
Cape Verdean00112
Dominican Republic00101
Captured as Hispanic or Latino in Database00011
Iranian00011
Indian00011
North African00011
Middle Eastern00011
Arab//North-African00011
White/Black/Asian00011
Mexican00022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Vehicle Cream BIDCohort A: Ruxolitinib 1.5% Cream BIDCohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BIDCohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Hispanic or Latino1113165393
Not Hispanic or Latino454399157344
Not Reported2131117
Unknown00011
Captured as Other in Database01023
08

Study locations

84 sites
  • Cahaba Dermatology
    Hoover, Alabama 35244, United States
  • Desert Sky Dermatology
    Gilbert, Arizona 85295, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Center For Dermatology Cosmetic and Laser Surgery
    Fremont, California 94538, United States
  • Marvel Clinical Research Llc
    Huntington Beach, California 92647, United States
  • Vitiligo & Pigmentation Institute of Southern California
    Los Angeles, California 90036, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Acrc Studies
    San Diego, California 92119, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Colorado Medical Research Center Inc
    Denver, Colorado 80210, United States
  • Harmony Medical Research Institute
    Hialeah, Florida 33016, United States
  • Advanced Pharma
    Miami, Florida 33147, United States
  • San Marcus Research Clinic Inc.
    Miami Lakes, Florida 33014, United States
  • Leavitt Medical Associates of Florida
    Ormond Beach, Florida 32174, United States
  • Avita Clinical Research
    Tampa, Florida 33613, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Forcare Clinical Research Fcr Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Randall Dermatology
    West Lafayette, Indiana 47906, United States
  • Delricht Clinical Research - Clinedge - Ppds Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Tufts Medical Center
    Boston, Massachusetts 02116, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Great Lakes Research Group Inc
    Bay City, Michigan 48706, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Minnesota Clinical Study Center
    Minneapolis, Minnesota 55432, United States
  • Jdr Dermatology Research
    Las Vegas, Nevada 89148, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Forest Hills Dermatology Group
    Kew Gardens, New York 11415, United States
  • The Dermatology Specialists Greenwich
    New York, New York 10012, United States
  • Icahn School of Medicine At Mount Sinai
    New York, New York 10029, United States
  • Derm Research Center of New York Inc
    Stony Brook, New York 11790, United States
  • Wake Research Associates Llc
    Raleigh, North Carolina 27612, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27104, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Kgl Skin Study Center
    Broomall, Pennsylvania 19008, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • Palmetto Clinical Trial Services
    Anderson, South Carolina 29621, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Innovative Dermatology
    Plano, Texas 75024, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • The Dermatology and Laser Center of San Antonio
    San Antonio, Texas 78229, United States
  • Clinical Research Partners Llc
    Richmond, Virginia 23226, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • Medical Center Unimed Eood
    Sevlievo, 05400, Bulgaria
  • Diagnostic Consultative Center Ii Sofia Eood
    Sofia, 01000, Bulgaria
  • University Multiprofile Hospital For Active Treatment Aleksandrovska
    Sofia, 01431, Bulgaria
  • Diagnostic Consultative Center Xxviii - Sofia - Eood
    Sofia, 01592, Bulgaria
  • Medical Center Eurohealth
    Sofia, 01606, Bulgaria
  • Dermatology Research Institute
    Calgary, Alberta T1Y 0B4, Canada
  • Simcoderm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • Skin Centre For Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Xlr8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Siena Medical Research Corporation
    Westmount, Quebec H3Z 2S6, Canada
  • Le Bateau Blanc
    Martigues, 13500, France
  • Hopital Archet 2 Derm Dept
    Nice, 06200, France
  • Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque
    Pessac, 33604, France
  • Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume
    Rouen, 76031, France
  • Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol
    Toulouse, 31059, France
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Hautarztpraxis Mahlow
    Mahlow, 15831, Germany
  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
    Mainz, 55131, Germany
  • Universitatsklinik Munster Dermatologie
    Münster, 48149, Germany
  • Amsterdam University Medical Centre
    Amsterdam, 1100 DD, Netherlands
  • Synexus - Polska Sp Z Oo Oddzial W Gdansk
    Gdansk, 80-382, Poland
  • Synexus Polska Sp. Z O.O. Oddzial W Gdyni
    Gdynia, 81-537, Poland
  • Synexus - Sp Z Oo Oddzial W Katowice
    Katowice, 40-040, Poland
  • Synexus Affiliate - Krakowskie Centrum Medyczne
    Krakow, 31-501, Poland
  • Synexus Polska Sp Z Oo Oddzial W Lodzi
    Lodz, 90-127, Poland
  • Synexus Polska Sp Z Oo Oddzial W Czestochowie
    Lublin, 20-081, Poland
  • Dermedic Dr. Zdybski
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Synexus Polska Sp. Z O.O. Oddzial W Poznaniu
    Poznan, 60-702, Poland
  • Lubeskie Centrum Diagnostyczne
    Świdnik, 21-040, Poland
  • Poradnia Dermatologiczno-Wenerologiczna Mediderm S.C. Nzoz
    Torun, 87-100, Poland
  • Synexus Polska Sp. Z O.O. Oddzial Warszawie
    Warsaw, 01-192, Poland
  • High-Med Przychodnia Specjalistycza
    Warsaw, 01-817, Poland
  • Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu
    Wroclaw, 50-381, Poland
  • Dermmedica Sp. Z O.O.
    Wroclaw, 51-318, Poland
  • Ico Hospital Germans Trias I Pujol
    Badalona, 08916, Spain
  • Dermomedic
    Madrid, 28001, Spain
  • Clinica Universidad de Navarra (Cun)
    Pamplona, 31008, Spain
09

References and documents

Publications

  • Rosmarin D, Pandya AG, Passeron T, Forman SB, Zdybski J, Amster M, Feser C, Papp KA, Nuara A, Kornacki D, Wei S, Ren H, Harris JE, Ezzedine K. Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatol Ther (Heidelb). 2025 Dec;15(12):3703-3716. doi: 10.1007/s13555-025-01555-3. Epub 2025 Oct 22. PubMed 41125994 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Nov 2022, 25 months.

Results were first posted in Jul 2023, 8 months after primary completion.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 28, 2020
StartActual
Sep 24, 2020
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 14, 2022
Results first posted
Jul 19, 2023
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04530344
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Sep 24, 2020
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Results posted
Jul 19, 2023
Last update
Aug 14, 2025

Study contacts

Kathleen Butler, MD
study chair · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion